In the context of perianal fistulizing Crohn's disease (PFCD), ustekinumab (UST) trough concentrations play a critical role in predicting clinical and radiological remission. A recent study has identified optimal trough levels for achieving fistula remission and managing the condition effectively.
In the context of perianal fistulizing Crohn's disease (PFCD), ustekinumab (UST) trough concentrations play a critical role in predicting clinical and radiological remission. A recent study has identified optimal trough levels for achieving fistula remission and managing the condition effectively.
The study found that UST trough concentrations ≥3.95 µg/mL at weeks 16/20 are predictive of fistula clinical remission, with an area under the curve (AUC) of 0.791, as determined by receiver operating characteristic (ROC) analysis. This threshold serves as a benchmark for therapeutic drug monitoring (TDM), helping to optimize dosing strategies for patients with PFCD. Additionally, the study highlighted that UST concentrations ≥2.75 µg/mL are associated with intestinal remission, indicating that fistulizing and luminal Crohn's disease may require different pharmacokinetic targets.
The findings underscore the importance of TDM in managing PFCD, as maintaining adequate UST trough levels can improve clinical outcomes, including fistula healing and systemic inflammation control. However, achieving and maintaining these trough levels may require dose adjustments or increased dosing frequency, which could lead to higher treatment costs. Despite this, the clinical benefits, such as reduced relapse rates, improved healing, and enhanced quality of life, justify the consideration of TDM in routine clinical practice for PFCD patients.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.